Esperion Therapeutics, Inc. Company Profile

Background

Overview

Esperion Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in Ann Arbor, Michigan. Founded in 2008, the company specializes in developing and commercializing innovative therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels, a major risk factor for cardiovascular diseases. Esperion's mission is to deliver effective, non-statin oral medications that address unmet needs in lipid management. The company's vision is to become a leading global biopharmaceutical entity by expanding its portfolio beyond cardiovascular diseases into rare hepatic and renal conditions.

Mission and Vision

• Mission: To deliver innovative medicines that help patients achieve their health goals today, tomorrow, and into the future.

• Vision: Innovation today, for healthier lives tomorrow.

Industry Significance

Esperion plays a pivotal role in the pharmaceutical industry by providing non-statin alternatives for LDL-C reduction, catering to patients who are statin-intolerant or require additional lipid-lowering therapies. The company's focus on oral, once-daily medications offers a convenient option for patients, potentially improving adherence and health outcomes.

Key Strategic Focus

Core Objectives

• Expand the U.S. cardiovascular franchise through increased market penetration and enhanced payer coverage.

• Advance the development of oral triple combination therapies to offer comprehensive lipid-lowering solutions.

• Broaden global reach by establishing strategic partnerships and securing regulatory approvals in key international markets.

Areas of Specialization

• Development of non-statin oral therapies for LDL-C reduction.

• Exploration of ACLY biology to identify novel therapeutic targets.

• Expansion into rare hepatic and renal diseases.

Key Technologies Utilized

• ATP-citrate lyase (ACLY) inhibitors for lipid management.

• Advanced clinical trial methodologies to support product efficacy and safety.

Primary Markets Targeted

• Patients with elevated LDL-C levels, including those with familial hypercholesterolemia and atherosclerotic cardiovascular disease.

• Statin-intolerant or statin-resistant individuals.

• Global markets, with a focus on Europe, Japan, Canada, and Australia.

Financials and Funding

Funding History

• As of February 2026, Esperion has raised approximately $273 million in funding, with the most recent round occurring on June 21, 2019, amounting to $200 million.

Recent Funding Rounds

• June 21, 2019: Raised $200 million.

Notable Investors

• Specific investor details are not publicly disclosed.

Utilization of Capital

• The capital has been allocated towards research and development of new therapies, commercialization efforts, and global expansion initiatives.

Pipeline Development

Key Pipeline Candidates

• ESP-2001: A highly specific allosteric ATP-citrate lyase inhibitor nominated as a preclinical development candidate for the treatment of primary sclerosing cholangitis (PSC). Investigational New Drug-enabling studies are underway, with plans to submit an IND to the FDA in 2026.

Stages of Development

• ESP-2001 is in the preclinical stage, with plans for clinical trials to commence in 2026.

Target Conditions

• Primary sclerosing cholangitis (PSC).

Anticipated Milestones

• IND submission to the FDA in 2026.

Technological Platform and Innovation

Proprietary Technologies

• ACLY inhibitors for lipid management.

Significant Scientific Methods

• Advanced clinical trial methodologies to support product efficacy and safety.

AI-Driven Capabilities

• Utilization of data science approaches to identify novel therapeutic targets.

Leadership Team

Key Executives

• Sheldon Koenig: Chief Executive Officer. He has been with Esperion since 2015, leading the company's strategic direction and growth initiatives.

• Brian J. S.: Chief Strategy Officer. He joined Esperion in 2018, focusing on strategic partnerships and business development.

• J. H.: Chief Commercial Officer. He has been with the company since 2017, overseeing global commercialization efforts.

Competitor Profile

Market Insights and Dynamics

• The cardiovascular disease market is highly competitive, with numerous pharmaceutical companies developing therapies for LDL-C reduction.

• Esperion differentiates itself by offering oral, non-statin therapies, catering to statin-intolerant patients.

Key Competitors

• Amgen Inc.: Offers Repatha (evolocumab), a PCSK9 inhibitor for LDL-C reduction.

• Regeneron Pharmaceuticals, Inc.: Provides Praluent (alirocumab), another PCSK9 inhibitor.

• Daiichi Sankyo: Partnered with Esperion for commercialization in Europe.

Strategic Collaborations and Partnerships

• Daiichi Sankyo Europe: Partnered for commercialization in Europe, with products launched in over 30 countries.

• Otsuka Pharmaceutical Co., Ltd.: Partnered for commercialization in Japan, with regulatory approval and favorable National Health Insurance pricing achieved.

• HLS Therapeutics: Partnered for commercialization in Canada, with NILEMDO approved and NEXLIZET expected in 2026.

• CSL Seqirus: Partnered for commercialization in Australia and New Zealand, with market approval expected in Q4 2026.

Operational Insights

• Esperion's strategic collaborations enhance its market reach and distribution capabilities, particularly in international markets.

• The company's focus on non-statin therapies positions it uniquely in the market, addressing the needs of statin-intolerant patients.

Strategic Opportunities and Future Directions

• Expansion into rare hepatic and renal diseases through the development of therapies like ESP-2001.

• Continued global expansion via strategic partnerships and regulatory approvals.

• Advancement of oral triple combination therapies to offer comprehensive lipid-lowering solutions.

Contact Information

• Official Website: www.esperion.com

• Social Media: LinkedIn, Twitter